ID   KKU-M214/GEM
AC   CVCL_HF58
DR   Wikidata; Q54900012
RX   PubMed=25998688;
CC   Problematic cell line: Contaminated. Parent cell line (KKU-213B) shown to be a KKU-M213 derivative.
CC   Population: Southeast Asian; Thai.
CC   Doubling time: 25.21 +- 1.88 hours (PubMed=25998688).
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M264 ! KKU-213B
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 11
//
RX   PubMed=25998688; DOI=10.3892/ijo.2015.3019;
RA   Wattanawongdon, Wareeporn
RA   Hahnvajanawong, Chariya
RA   Namwat, Nisana
RA   Kanchanawat, Sirimas
RA   Boonmars, Thidarut
RA   Jearanaikoon, Patcharee
RA   Leelayuwat, Chanwit
RA   Techasen, Anchalee
RA   Seubwai, Wunchana
RT   "Establishment and characterization of gemcitabine-resistant human
RT   cholangiocarcinoma cell lines with multidrug resistance and enhanced
RT   invasiveness.";
RL   Int. J. Oncol. 47:398-410(2015).
//